United States Carotid Stent Market to Reach USD 1,047.53 Million by 2033 | Metals Segment Holds 70% Share, Driving Innovation and Growth in Cardiovascular Interventions

Market Size & Growth

The global Carotid Stent Market was valued at US$ 622.76 million in 2024 and is projected to reach US$ 1,047.53 million by 2033, growing at a CAGR of 6.0% during the forecast period 2025-2033. The market expansion is driven by increasing prevalence of carotid artery diseases, rising geriatric population, advancements in minimally invasive stenting procedures, and adoption of innovative materials and stent designs.

Carotid stents are medical devices designed to restore and maintain normal blood flow in narrowed or blocked carotid arteries, which supply blood to the brain. By preventing or reducing the risk of ischemic stroke, these stents play a crucial role in vascular and neurological health management. They are typically available as self-expanding or balloon-expandable stents and are most commonly used in conjunction with angioplasty procedures to widen the artery and stabilize the vessel wall, offering a minimally invasive alternative to carotid endarterectomy surgery.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/carotid-stent-market?juli

Recent Developments:

United States
✅ October 2025: Abbott Laboratories launched an advanced self-expanding carotid stent system offering superior flexibility and reduced restenosis risk, improving procedural outcomes for stroke prevention.

✅ August 2025: Boston Scientific Corporation expanded its U.S. distribution network to introduce next-generation balloon-expandable carotid stents, enhancing accessibility across major cardiac centers.

✅ May 2025: Medtronic Plc integrated AI-assisted vascular imaging technology into its stent delivery systems to enable more precise deployment and real-time procedural monitoring.

Global
✅ September 2025: MicroPort Scientific Corporation introduced its advanced nitinol-based carotid stents across European cardiac hospitals, providing enhanced radial strength and long-term durability.

✅ June 2025: Shanghai Hengfei Biological Technology Co., Ltd. launched cost-effective self-expanding carotid stents in Asia-Pacific markets to improve affordability and access in emerging economies.

✅ March 2025: BIOTRONIK SE & Co. KG entered into partnerships with leading Middle Eastern healthcare providers to deploy drug-eluting carotid stents designed for high-risk patient populations.

Mergers & Acquisitions:

United States
✅ July 2025: Cardinal Health acquired a precision stent manufacturing startup to strengthen its carotid and peripheral vascular device portfolio, expanding its presence in minimally invasive cardiovascular care.

Europe & Asia-Pacific
✅ February 2025: W. L. Gore & Associates collaborated with European cardiovascular firms to co-develop next-generation flexible carotid stents, integrating advanced biocompatible materials for improved patient safety.

✅ January 2025: Shanghai Zhenyu Biological Technology Co., Ltd. expanded strategic partnerships with regional distributors to increase its market penetration and product accessibility across the Asia-Pacific region.

Key Players :
Abbott Laboratories | Boston Scientific Corporation | Cardinal Health | Medtronic Plc | Terumo Corporation | MicroPort Scientific Corporation | W. L. Gore & Associates | BIOTRONIK SE & Co. KG | InspireMD | Impulse Dynamics | Shanghai Hengfei Biological Technology Co., Ltd. | Beijing Bomais Technology Development | Shanghai Zhenyu Biological Technology Co., Ltd. | Shanghai Haoran Biotechnology Co., Ltd.

Key Highlights:

-Abbott Laboratories 16.2% market share: Leads the global market through its innovative self-expanding and drug-eluting carotid stents, supported by strong clinical research, FDA approvals, and wide hospital adoption across North America and Europe.

-Boston Scientific Corporation 14.5% market share: Focuses on advanced balloon-expandable stent systems, known for precision placement, reduced restenosis rates, and integration with digital vascular imaging platforms.

-Medtronic Plc 13.8% market share: Recognized for its AI-assisted imaging and navigation technologies, supporting minimally invasive carotid stenting and superior procedural safety outcomes.

-Cardinal Health 8.6% market share: Strengthened its position through strategic acquisitions in precision stent manufacturing, expanding its endovascular product portfolio across hospitals and cardiac centers.

-Terumo Corporation 7.5% market share: Drives growth through high-performance stent delivery systems and growing adoption of its minimally invasive vascular solutions across Asia and Europe.

-MicroPort Scientific Corporation 7.2% market share: Expanding global presence with cost-effective nitinol-based stents and increasing penetration in emerging cardiovascular markets.

-W. L. Gore & Associates 6.9% market share: Known for flexible, biocompatible stent materials and collaborations with European cardiovascular institutions on next-generation designs.

-BIOTRONIK SE & Co. KG 6.1% market share: A key player in drug-eluting and hybrid stent technologies, supported by strategic partnerships in the Middle East and Europe.

-InspireMD 4.8% market share: Specializes in micro-mesh-protected stent systems aimed at preventing embolic complications during carotid procedures.

-Impulse Dynamics 3.9% market share: Focused on integrating stent technologies with cardiac monitoring systems to improve long-term outcomes in vascular patients.

-Shanghai Hengfei Biological Technology Co., Ltd. 2.8% market share: Expanding rapidly in Asia-Pacific with affordable self-expanding carotid stents tailored for emerging healthcare systems.

-Beijing Bomais Technology Development 2.4% market share: Strengthening domestic market presence through R&D in biocompatible materials and advanced production facilities.

-Shanghai Zhenyu Biological Technology Co., Ltd. 2.3% market share: Focused on partnership-driven distribution of hybrid stent technologies across regional markets.

-Shanghai Haoran Biotechnology Co., Ltd. 2.0% market share: Specializes in polymeric and customized carotid stent solutions targeting developing nations with scalable production capacity.

-Together, these companies account for approximately 95% of the global Carotid Stent Market, with established players like Abbott, Boston Scientific, and Medtronic leading innovation through next-generation stent designs, digital integration, and global clinical expansion, while emerging Asian manufacturers are driving accessibility and cost optimization in fast-growing regional markets.

Market Segmentation:

➥ By material, metals dominate with a 70% market share, primarily due to their high tensile strength, durability, and proven clinical performance in carotid revascularization procedures. Other stents account for the remaining 30%, encompassing polymeric and drug-eluting stents that offer enhanced biocompatibility and controlled drug release for specialized medical applications.

➥ By type, self-expanding stents hold 60% of the market, favored for their superior flexibility, adaptability to tortuous carotid arteries, and reduced risk of vessel recoil. In contrast, balloon-expandable stents represent 40%, widely used in controlled lesion settings where precision deployment and stability are critical.

➥ By end-user, hospitals lead with a 65% share, driven by high patient volumes, advanced imaging capabilities, and access to skilled interventional cardiologists. Ambulatory Surgical Centers (ASCs) account for 20%, reflecting a growing preference for outpatient and minimally invasive procedures that offer reduced recovery times and cost efficiency. Cardiac Centers represent the remaining 15%, focusing on specialized interventions and adoption of cutting-edge carotid stent technologies for complex vascular cases.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=carotid-stent-market?Juli

Regional Insights:
The Carotid Stent Market exhibits strong regional diversity, with North America leading at 40% market share. The United States dominates this region, supported by an advanced interventional cardiology infrastructure, early adoption of drug-eluting and self-expanding stents, and a high procedural volume of carotid revascularizations. Continuous innovation and favorable reimbursement policies further reinforce the region's leadership in minimally invasive cardiovascular treatments.

Europe accounts for 30% of the global market, driven by regulatory approvals for novel carotid stent technologies, growing preference for minimally invasive interventions, and increasing investments in hospital imaging and vascular treatment facilities. Countries such as Germany, France, and the United Kingdom are key contributors to this growth due to their strong clinical adoption and government-backed healthcare advancements.

The Asia-Pacific region represents 20% of the market, growing at a CAGR of 7.2%. Rapid expansion in China, Japan, and India is fueled by the rising prevalence of cardiovascular diseases, improving healthcare infrastructure, and greater accessibility to innovative and cost-effective stent technologies from regional manufacturers.

Latin America, the Middle East, and Africa (LAMEA) collectively account for 10% of the global market. Growth in these regions is supported by government-led healthcare modernization programs, increasing awareness of stroke prevention, and the rising establishment of advanced cardiac care centers across major urban hubs.

Speak to Our Analyst and Get Customization in the report as per your requirements:https://www.datamintelligence.com/customize/carotid-stent-market?juli

Market Dynamics:
Drivers:
The growth of the Carotid Stent Market is fueled by the rising global incidence of carotid artery stenosis and the associated stroke risk, prompting increased demand for preventive interventions. There is a growing preference for minimally invasive procedures over open surgical methods, which reduces patient recovery time and procedural risk. Additionally, technological innovations in stent design, drug-eluting coatings, and imaging integration are enhancing clinical outcomes, precision, and safety, further propelling market expansion.

Restraints:
Market growth faces challenges due to the high cost of advanced carotid stents and associated procedural expenses, which can limit adoption in cost-sensitive regions. Stringent regulatory approvals and compliance with quality and safety standards increase time-to-market and operational complexity. Moreover, there remains a risk of restenosis and procedural complications, particularly among high-risk patient populations, which may impact physician preference and market penetration.

Opportunities:
Significant opportunities exist in the development of next-generation stents, including drug-eluting, biodegradable, and AI-guided stents that improve patient outcomes. Emerging markets with growing awareness of cardiovascular diseases offer potential for expansion and higher adoption rates. Integration with robotic-assisted surgery and image-guided interventional platforms presents further avenues to enhance procedural precision, reduce complications, and establish competitive differentiation in the global market.

📌 Request for 2 Days FREE Trial Access: https://www.datamintelligence.com/reports-subscription

☛ Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape

✅ Sustainability Impact Analysis

✅ KOL / Stakeholder Insights

✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots

✅ Market Volatility & Emerging Risks Analysis

✅ Quarterly Industry Report Updated

✅ Live Market & Pricing Trends

✅ Import-Export Data Monitoring

☛ Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg?Juli

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.